论文部分内容阅读
目的DNA定量鉴别乳腺导管非典型增生与原位癌、原位癌及浸润癌。方法对乳腺导管非典型增生(7例)、原位癌(15例)及浸润癌(18例)共计40例进行细胞涂片,Feulgen染色,全自动图像分析仪进行细胞核定量检测。结果乳腺导管非典型增生及原位癌均未见DNA异倍体,未出现五倍体(5c)细胞,两组间DNA指数及S期细胞比率有统计学差别(P<0.05)。浸润癌检测到大量DNA异倍体,出现五倍体(5c)细胞,DNA指数及S期细胞比率高于原位癌,但不具有统计学差别(P>0.05)。结论利用图像分析仪检测DNA含量、S期细胞比率对乳腺导管非典型增生与原位癌的鉴别、原位癌与浸润癌的鉴别具有一定的临床意义。
Objective DNA quantitative identification of atypical ductal hyperplasia and carcinoma in situ, carcinoma in situ and invasive carcinoma. Methods A total of 40 cases of atypical hyperplasia (7 cases), in situ carcinoma (15 cases) and invasive carcinoma (18 cases) were examined by cell smear, Feulgen staining and automatic image analyzer. Results There was no DNA aneuploidy in atypical hyperplasia and carcinoma in situ, and no pentaploid (5c) cells appeared. There was a significant difference in DNA index and S phase between the two groups (P <0.05). A large amount of DNA aneuploidy was found in invasive carcinoma. The occurrence of pentaploid (5c) cells, DNA index and S phase cells were higher than that in situ carcinoma, but there was no statistical difference (P> 0.05). Conclusion The detection of DNA content using image analyzer, S-cell ratio of breast ductal atypical hyperplasia and carcinoma in situ identification, in situ carcinoma and invasive cancer has some clinical significance.